Grace Therapeutics (GRCE) Projected to Announce Quarterly Earnings on Thursday

Grace Therapeutics (NASDAQ:GRCE) is expected to be announcing its Q2 2027 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $1.00 million for the quarter. Investors can check the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Grace Therapeutics (NASDAQ:GRCE) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.78). During the same period in the previous year, the firm earned ($0.21) EPS.

Grace Therapeutics Stock Performance

Shares of Grace Therapeutics stock opened at $1.86 on Tuesday. The company has a fifty day moving average of $2.03 and a 200-day moving average of $2.78. Grace Therapeutics has a 52-week low of $1.67 and a 52-week high of $5.18. The stock has a market capitalization of $39.24 million, a price-to-earnings ratio of -1.58 and a beta of 0.43.

Analysts Set New Price Targets

A number of equities analysts have commented on GRCE shares. Zacks Research raised Grace Therapeutics to a “hold” rating in a research note on Monday, August 3rd. Wall Street Zen cut Grace Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biopharmaceutical company developing therapies for rare and life-threatening medical conditions. The company focuses on drug-delivery technologies intended to improve the administration, absorption, and therapeutic performance of established pharmaceutical compounds.

Grace Therapeutics’ lead candidate is GTx-104, an investigational injectable formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, a serious form of bleeding around the brain.